Amgen-Kyowa Antibody Deal Worth Up To $520 Million
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech licenses single molecule for inflammatory disease, future oncology use.
You may also be interested in...
Takeda Makes $1 Billion Move For Amgen Development Rights
Agreement includes Japanese rights to Vectibix.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
Alzheimer’s, BRAIN Initiative Highlighted In $30 Billion NIH Budget Proposal
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.